Literature DB >> 3094512

The HTLV-III envelope protein contains a hexapeptide homologous to a region of interleukin-2 that binds to the interleukin-2 receptor.

D A Weigent, P D Hoeprich, K L Bost, T K Brunck, W E Reiher, J E Blalock.   

Abstract

A region of human interleukin-2 (IL-2) which was predicted to be a contact point with its receptor was used to locate a homologous region in the envelope protein of human T-lymphotropic retrovirus (HTLV-III). This homologous six amino acid peptide from the carboxy (C)-terminus of the HTLV-III envelope protein was found to inhibit the biological activity of human IL-2 in a murine spleen cell proliferation assay. When conjugated to a carrier protein, this peptide inhibited the binding of radiolabelled IL-2 to its receptor. The biological activity of the peptide was antagonized by a six amino acid peptide fragment of the IL-2 receptor which was predicted to be the contact point on the receptor that corresponded to the binding region of IL-2. The HTLV-III peptide also inhibited the binding of radiolabelled IL-2 to polyclonal anti-IL-2 antiserum. These data support the previous assignment of contact points between IL-2 and its receptor. They also suggest two possible mechanisms of immunosuppression during acquired immunodeficiency syndrome (AIDS). One involves direct competition of the envelope protein or its fragments with IL-2 for binding to the IL-2 receptor. The other involves antibodies to the envelope protein which crossreact with and neutralize IL-2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094512     DOI: 10.1016/s0006-291x(86)80123-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Molecular mimicry as a mechanism for virus-induced autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Retrovirus and filovirus "immunosuppressive motif" and the evolution of virus pathogenicity in HIV-1, HIV-2, and Ebola viruses.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

3.  Individuals infected with HIV possess antibodies against IL-2.

Authors:  K L Bost; B H Hahn; M S Saag; G M Shaw; D A Weigent; J E Blalock
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

4.  Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals.

Authors:  H Golding; G M Shearer; K Hillman; P Lucas; J Manischewitz; R A Zajac; M Clerici; R E Gress; R N Boswell; B Golding
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  Design and recognition properties of a hydropathically complementary peptide to human interleukin 1 beta.

Authors:  G Fassina; G Cassani
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

6.  Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2.

Authors:  W E Reiher; J E Blalock; T K Brunck
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Herpes simplex virus-infected cells disarm killer lymphocytes.

Authors:  D L Confer; G M Vercellotti; D Kotasek; J L Goodman; A Ochoa; H S Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Common immunologic determinant between human immunodeficiency virus type 1 gp41 and astrocytes.

Authors:  M Yamada; A Zurbriggen; M B Oldstone; R S Fujinami
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Computer predictions of functional, topogenic, and antigenic domains in human immunodeficiency virus-2 envelope glycoprotein.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1992-01       Impact factor: 2.332

10.  Computer analysis of human immunodeficiency virus-1 envelope glycoprotein: functional topogenic domains as signals for transfer and cleavage.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1991-10       Impact factor: 2.332

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.